Status:
NOT_YET_RECRUITING
Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Carbapenem-Resistant Enterobacteriaceae Infection
Eligibility:
All Genders
18+ years
Brief Summary
Severe infections caused by carbapenem-resistant Enterobacterales (CRE) represent a challenge for the clinicians, considering the high mortality rate of these infections. Data regarding the prevalence...
Eligibility Criteria
Inclusion
- age ≥ 18 years;
- isolation of CRE from a clinically relevant sample considered to be the site of infection: pneumonia, UTI, IAI, spondylodiscitis and BSI.
- Patients who by clinical practice have received at least one dose of the following drugs from ceftazidime-avibactam, meropenem-vaborbactam, and cefiderocol.
- Signature of Informed Consent
Exclusion
- Subjects under 18 years of age
- absence of CRE infections
Key Trial Info
Start Date :
September 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT07160569
Start Date
September 1 2025
End Date
August 31 2026
Last Update
September 8 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universtiario Agostino Gemelli IRCCS
Rome, Roma, Italy, 00168
2
Unit of Infectious and Tropical Diseases, Azienda Ospedaliera "Cannizzaro", Catania
Catania, Italy
3
Unit of Infectious and Tropical Diseases, University "Magna Graecia", Catanzaro
Catanzaro, Italy
4
Unit of Infectious and Tropical Diseases, Azienda Ospedaliera "Bianchi-Melacrino-Morelli", Reggio Calabria
Reggio Calabria, Italy